This vaccine may induce the production of high antibody titers and can increase the secretion of IFN-γ by Th1 cells and IL-6 by Th2 cells to promote the activity of CD4+ and CD8+ T cells, which have desirable synergistic effects for combating tumor growth and prolonging survival after subcutaneous administration in BALB/c mice using a prime-boost immunization schedule. Here, CD8A is linked to neoplasm.